Back to results
US 12,583,915 B2Granted
Methods for diagnosing cancer using anti-BAG2 antibody
AssigneesMedpacto Inc., Yonsei University Medical College, Gangnam Severance Hospital, Dept of Surgery, Sungkyunkwan University, Dept of Biological Sciences
InventorsSeong Jin Kim, Kyung-Min Yang, Joon Jeong, Sung Gwe Ahn, Seok Hee Park, Dong Woo Kang
Life of this patent
Estimating the term…
Abstract
The present application discloses a composition for use in diagnosing cancer, the composition comprising: an antibody or antigen-binding fragment thereof that specifically binds to a BAG2 polypeptide or fragment thereof.
Claims16
A composition for use in diagnosing cancer, the composition comprising:
- an antibody or antigen-binding fragment thereof comprising a heavy chain variable region comprising VH-CDR1 consisting of the amino acid sequence of SEQ ID NO:
- 33, VH-CDR2 consisting of the amino acid sequence of SEQ ID NO:
- 39 in which 6th Xaa and 7th Xaa are each Gly, and VH-CDR3 consisting of the amino acid sequence of SEQ ID NO:
- 45 and a light chain variable region comprising VL-CDR1 consisting of the amino acid sequence of SEQ ID NO:
- 51, VL-CDR2 consisting of the amino acid sequence of SEQ ID NO:
- 57, and VL-CDR3 consisting of the amino acid sequence of SEQ ID NO:
- 63;
- and
- an antibody or antigen-binding fragment thereof comprising a heavy chain variable region comprising a VH-CDR1 consisting of the amino acid sequence of SEQ ID NO:
- 38, VH-CDR2 consisting of the amino acid sequence of SEQ ID NO:
- 44, and VH-CDR3 consisting of the amino acid sequence of SEQ ID NO:
- 50;
- and a light chain variable region comprising a VL-CDR1 consisting of the amino acid sequence of SEQ ID NO:
- 56, VL-CDR2 consisting of the amino acid sequence of SEQ ID NO:
- 62, and VL-CDR3 consisting of the amino acid sequence of SEQ ID NO:
- 68.
13 more elements
A composition for use in diagnosing cancer, the composition comprising:
- an antibody or antigen-binding fragment thereof comprising a heavy chain variable region comprising VH-CDR1 consisting of the amino acid sequence of SEQ ID NO:
- 35 in which 2nd Xaa is Tyr, VH-CDR2 consisting of the amino acid sequence of SEQ ID NO:
- 41 in which 8th Xaa is Ser, and VH-CDR3 consisting of the amino acid sequence of SEQ ID NO:
- 47 in which 12th Xaa is His and a light chain variable region comprising VL-CDR1 consisting of the amino acid sequence of SEQ ID NO:
- 53 in which 3rd Xaa is Met, VL-CDR2 consisting of the amino acid sequence of SEQ ID NO:
- 59 in which 2nd Xaa is Ala, and VL-CDR3 consisting of amino acid sequence of SEQ ID NO:
- 65;
- and
- an antibody or antigen-binding fragment thereof comprising a heavy chain variable region comprising a VH-CDR 1 consisting of the amino acid sequence of SEQ ID NO:
- 37, VH-CDR2 consisting of the amino acid sequence of SEQ ID NO:
- 43, and VH-CDR3 consisting of the amino acid sequence of SEQ ID NO:
- 49;
- and a light chain variable region comprising a VL-CDR1 consisting of the amino acid sequence of SEQ ID NO:
- 55, VL-CDR2 consisting of the amino acid sequence of SEQ ID NO:
- 61, and VL-CDR3 consisting of the amino acid sequence of SEQ ID NO:
- 67.
13 more elements
A composition for use in diagnosing cancer, the composition comprising:
- an antibody or antigen-binding fragment thereof comprising a heavy chain variable region comprising VH-CDR1 consisting of the amino acid sequence of SEQ ID NO:
- 33, VH-CDR2 consisting of the amino acid sequence of SEQ ID NO:
- 39 in which 6th Xaa and 7th Xaa are Ala and Gly, respectively, and VH-CDR3 consisting of the amino acid sequence of SEQ ID NO:
- 45 and a light chain variable region comprising VL-CDR1 consisting of the amino acid sequence of SEQ ID NO:
- 51, VL-CDR2 consisting of the amino acid sequence of SEQ ID NO:
- 57, and VL-CDR3 consisting of the amino acid sequence of SEQ ID NO:
- 63;
- and
- an antibody or antigen-binding fragment thereof comprising a heavy chain variable region comprising a VH-CDR 1 consisting of the amino acid sequence of SEQ ID NO:
- 37, VH-CDR2 consisting of the amino acid sequence of SEQ ID NO:
- 43, and VH-CDR3 consisting of the amino acid sequence of SEQ ID NO:
- 49;
- and a light chain variable region comprising a VL-CDR1 consisting of the amino acid sequence of SEQ ID NO:
- 55, VL-CDR2 consisting of the amino acid sequence of SEQ ID NO:
- 61, and VL-CDR3 consisting of the amino acid sequence of SEQ ID NO:
- 67.
13 more elements
A composition for use in diagnosing cancer, the composition comprising:
- an antibody or antigen-binding fragment thereof comprising a heavy chain variable region comprising a VH-CDR 1 consisting of the amino acid sequence of SEQ ID NO:
- 38, VH-CDR2 consisting of the amino acid sequence of SEQ ID NO:
- 44, and VH-CDR3 consisting of the amino acid sequence of SEQ ID NO:
- 50;
- and a light chain variable region comprising a VL-CDR1 consisting of the amino acid sequence of SEQ ID NO:
- 56, VL-CDR2 consisting of the amino acid sequence of SEQ ID NO:
- 62, and VL-CDR3 consisting of the amino acid sequence of SEQ ID NO:
- 68;
- and
- an antibody or antigen-binding fragment thereof comprising a heavy chain variable region comprising a VH-CDR 1 consisting of the amino acid sequence of SEQ ID NO:
- 37, VH-CDR2 consisting of the amino acid sequence of SEQ ID NO:
- 43, and VH-CDR3 consisting of the amino acid sequence of SEQ ID NO:
- 49;
- and a light chain variable region comprising a VL-CDR1 consisting of the amino acid sequence of SEQ ID NO:
- 55, VL-CDR2 consisting of the amino acid sequence of SEQ ID NO:
- 61, and VL-CDR3 consisting of the amino acid sequence of SEQ ID NO:
- 67.
14 more elements
Dependencies are inferred from the claim text.